Fresenius Medical Care AG: Form 20-F for the period ended Dec 31, 2011
Filed with the SEC on Feb 23, 2012 and accepted by EDGAR at Feb 23, 2012, 16:23 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2011-01-01 to 2011-12-31 | $8.27bn | us-gaap:CostOfRevenue |
| Gross profit | 12 months2011-01-01 to 2011-12-31 | $4.52bn | us-gaap:GrossProfit |
| Research and development | 12 months2011-01-01 to 2011-12-31 | $110.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2011-01-01 to 2011-12-31 | $2.37bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2011-01-01 to 2011-12-31 | $2.07bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2011-01-01 to 2011-12-31 | $356.4m | us-gaap:InterestExpense |
| Income tax | 12 months2011-01-01 to 2011-12-31 | $601.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2011-01-01 to 2011-12-31 | $1.07bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2011-01-01 to 2011-12-31 | $3.51 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2011-01-01 to 2011-12-31 | $3.54 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2011-01-01 to 2011-12-31 | 300,808,487 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2011-01-01 to 2011-12-31 | $1.45bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2011-01-01 to 2011-12-31 | $597.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2011-01-01 to 2011-12-31 | $280.6m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2011-12-31 | $457.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-12-31 | $5.70bn | us-gaap:AssetsCurrent |
| Total assets | At period end2011-12-31 | $19.53bn | us-gaap:Assets |
| Current liabilities | At period end2011-12-31 | $4.26bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-12-31 | $11.06bn | us-gaap:Liabilities |
| Long-term debt | At period end2011-12-31 | $5.49bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2011-12-31 | $126.8m | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2011-12-31 | $98.8m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2011-12-31 | $7.90bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2011-12-31 | 300,164,922 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000950123-12-002984. Last ingested by Listed: Nov 14, 2026, 17:40 ET. Listed shows no prices and gives no investment advice.